Cargando…

A reply to ‘Metabolic effects of sapropterin treatment in autism spectrum disorder: a preliminary study'

Detalles Bibliográficos
Autor principal:	Fluegge, K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872393/ https://www.ncbi.nlm.nih.gov/pubmed/27115124 http://dx.doi.org/10.1038/tp.2016.24

Ejemplares similares

Metabolic effects of sapropterin treatment in autism spectrum disorder: a preliminary study
por: Frye, R E, et al.
Publicado: (2013)

A reply to ‘Alteration of steroidogenesis in boys with autism spectrum disorders’
por: Gasser, Benedikt Andreas, et al.
Publicado: (2021)

Zinc and Copper Metabolism and Risk of Autism: a reply to Sayehmiri et al
por: FLUEGGE BA, Keith
Publicado: (2017)

New era in treatment for phenylketonuria: Pharmacologic therapy with sapropterin dihydrochloride
por: Harding, Cary O
Publicado: (2010)

Sapropterin Dihydrochloride Mixed With Common Foods and Beverages
por: Jurecki, Elaina R., et al.
Publicado: (2014)

Sapropterin for phenylketonuria: A Japanese post‐marketing surveillance study
por: Tamura, Mina, et al.
Publicado: (2022)

The potential role of nitrous oxide in the etiology of autism spectrum disorder
por: Frye, R E, et al.
Publicado: (2016)

Reply: Low bone mineral density is a common feature of Zellweger spectrum disorders
por: Klouwer, Femke C.C., et al.
Publicado: (2016)

Reply: Low bone mineral density is a common feature of Zellweger spectrum disorders
por: Rush, Eric T., et al.
Publicado: (2016)

Sapropterin (BH4) Aggravates Autoimmune Encephalomyelitis in Mice
por: Schmitz, Katja, et al.
Publicado: (2021)

HPLC-Based Analysis of Impurities in Sapropterin Branded and Generic Tablets
por: Scudellaro, Emanuela, et al.
Publicado: (2020)

Sapropterin Treatment Prevents Congenital Heart Defects Induced by Pregestational Diabetes Mellitus in Mice
por: Engineer, Anish, et al.
Publicado: (2018)

Longitudinal quality of life analysis in a phenylketonuria cohort provided sapropterin dihydrochloride
por: Douglas, Teresa D, et al.
Publicado: (2013)

Reply to Comment on: The Impact of COVID-19 on Individuals Across the Spectrum of Visual Impairment
por: Shukla, Aakriti Garg, et al.
Publicado: (2021)

Application of Telemedicine for Preliminary Screening of Autism Spectrum Disorder
por: Qiu, Ting, et al.
Publicado: (2022)

Clinical audit for occupational therapy intervention for children with autism spectrum disorder: sampling steps and sample size calculation
por: Weeks, Scott, et al.
Publicado: (2015)

Treatment of Folate Metabolism Abnormalities in Autism Spectrum Disorder
por: Frye, Richard E., et al.
Publicado: (2020)

A Prospective Population Pharmacokinetic Analysis of Sapropterin Dihydrochloride in Infants and Young Children with Phenylketonuria
por: Qi, Yulan, et al.
Publicado: (2014)

Hypermobile spectrum disorders symptoms in patients with functional neurological disorders and autism spectrum disorders: A preliminary study
por: Nisticò, Veronica, et al.
Publicado: (2022)

Pretreatment cognitive and neural differences between sapropterin dihydrochloride responders and non-responders with phenylketonuria
por: Hawks, Zoë, et al.
Publicado: (2017)

Neuropsychiatric disorders and COVID-19 – Authors' reply
por: Taquet, Maxime, et al.
Publicado: (2021)

Long-term efficacy and safety of sapropterin in patients who initiated sapropterin at < 4 years of age with phenylketonuria: results of the 3-year extension of the SPARK open-label, multicentre, randomised phase IIIb trial
por: Muntau, Ania C., et al.
Publicado: (2021)

Reply
por: Cheung, Ka Shing, et al.
Publicado: (2021)

Reply
por: Xu, Zhilu, et al.
Publicado: (2021)

Reply
por: Zhang, Lin, et al.
Publicado: (2022)

Efficacy and safety of sapropterin dihydrochloride in patients with phenylketonuria: A meta‐analysis of randomized controlled trials
por: Qu, Jinghan, et al.
Publicado: (2019)

Reply
por: Roscam Abbing, Reinout L.P., et al.
Publicado: (2020)

Does antipsychotic use mediate the effect of psychiatric disorders on COVID-19? – Authors' reply
por: Yang, Huazhen, et al.
Publicado: (2021)

In Reply: Outcomes and Spectrum of Major Neurovascular Events Among COVID-19 Patients: A 3-Center Experience
por: Taylor, Blake E S, et al.
Publicado: (2021)

Author's Reply
por: Mukhopadhyay, Amiya K
Publicado: (2020)

Characterising neuropsychiatric disorders in patients with COVID-19 – Authors' reply
por: Varatharaj, Aravinthan, et al.
Publicado: (2020)

Two bipolar disorders or one? In reply to commentary by Malhi and Bell
por: Tondo, Leonardo, et al.
Publicado: (2022)

Clinical overlap between functional neurological disorders and autism spectrum disorders: a preliminary study
por: Nisticò, Veronica, et al.
Publicado: (2022)

Clinical overlap between functional neurological disorders and autism spectrum disorders: a preliminary study
por: Goeta, D., et al.
Publicado: (2023)

Authors’ reply
por: Mathaiyan, Jayanthi, et al.
Publicado: (2015)

Authors’ Reply
por: Padhiyar, Jigna K, et al.
Publicado: (2019)

Comparison of the Autism Diagnostic Observation Schedule and Childhood Autism Rating Scale in the Diagnosis of Autism Spectrum Disorder: A Preliminary Study
por: Park, Hyung Seo, et al.
Publicado: (2018)

Author's Reply
por: Kaeberlein, Matt, et al.
Publicado: (2006)

Telemonitoring of children with risk indicators for Autism Spectrum Disorder: preliminary findings
por: da Silva, Alessandra Pinheiro, et al.
Publicado: (2023)

Reply
por: Yang, Xu, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_pfu9hlj8jqpl2lc887h500m7ij